Cargando…
Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis
BACKGROUND: An increasing number of studies evidences that amyotrophic lateral sclerosis (ALS) is characterized by extensive alterations in different cell types and in different regions besides the CNS. We previously reported the upregulation in ALS models of a gene called fibroblast-specific protei...
Autores principales: | Milani, Martina, Mammarella, Eleonora, Rossi, Simona, Miele, Chiara, Lattante, Serena, Sabatelli, Mario, Cozzolino, Mauro, D’Ambrosi, Nadia, Apolloni, Savina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196441/ https://www.ncbi.nlm.nih.gov/pubmed/34118929 http://dx.doi.org/10.1186/s12974-021-02184-1 |
Ejemplares similares
-
The S100A4 Transcriptional Inhibitor Niclosamide Reduces Pro-Inflammatory and Migratory Phenotypes of Microglia: Implications for Amyotrophic Lateral Sclerosis
por: Serrano, Alessia, et al.
Publicado: (2019) -
Repurposing niclosamide for the treatment of neurological disorders
por: Apolloni, Savina, et al.
Publicado: (2023) -
Fibrosis as a common trait in amyotrophic lateral sclerosis tissues
por: Apolloni, Savina, et al.
Publicado: (2021) -
S100A4 in the Physiology and Pathology of the Central and Peripheral Nervous System
por: D’Ambrosi, Nadia, et al.
Publicado: (2021) -
The Contribution of Non-Neuronal Cells in Neurodegeneration: From Molecular Pathogenesis to Therapeutic Challenges
por: D’Ambrosi, Nadia, et al.
Publicado: (2022)